Rationale and design of the LEADERS FREE trial: A randomized double-blind comparison of the BioFreedom drug-coated stent vs the Gazelle bare metal stent in patients at high bleeding risk using a short (1 month) course of dual antiplatelet therapy

医学 支架 随机对照试验 外科 裸金属 双盲 替代医学 病理 再狭窄 安慰剂
作者
Philip Urban,Alexandre Abizaid,Bernard Chevalier,Samantha Greene,Ian T. Meredith,Marie‐Claude Morice,Stuart Pocock
出处
期刊:American Heart Journal [Elsevier BV]
卷期号:165 (5): 704-709 被引量:72
标识
DOI:10.1016/j.ahj.2013.01.008
摘要

Major bleeding is a powerful predictor of morbidity and mortality after percutaneous coronary intervention (PCI). To avoid prolonged dual antiplatelet therapy (DAPT), current guidelines recommend using a bare metal stent when PCI is indicated to treat patients at high risk of bleeding. The Biolimus A9-coated BioFreedom is a new stainless steel drug-coated stent devoid of polymer and has been shown to be associated with a low median late-loss of 0.17 mm at 12 months of follow-up. In an animal model, 98% of the drug has diffused into the vessel wall at 1 month. It is therefore reasonable to consider that such a device may have a potential safety advantage, and a lesser dependence on prolonged DAPT than a polymer-coated drug-eluting stent.A total of 2456 patients considered at high risk of bleeding will be randomized in a double-blind fashion to the BioFreedom drug-coated stent or to a control arm (Gazelle bare metal stent). Both groups will be treated with DAPT during 1 month only, followed by long-term aspirin alone. At 1-year follow-up, the primary safety endpoint (a composite of cardiac death, myocardial infarction and stent thrombosis) will be assessed by a non-inferiority analysis, and the primary efficacy endpoint (clinically driven target lesion revascularization) by a superiority analysis.This trial should help better characterize a neglected subset of PCI patients and quantify both their thrombotic and bleeding risks. It has the potential to decrease the need for target lesion revascularization in patients unable to tolerate a prolonged course of DAPT and will assess the shortest DAPT course ever used with an active stent.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
万能图书馆的应助被小鞠佩奇采纳,获得10
2秒前
yyys完成签到,获得积分10
2秒前
Berta关注了科研通微信公众号
2秒前
烟花的应助被胡萝贝采纳,获得10
2秒前
李健的小迷弟的应助被FU采纳,获得10
2秒前
CC发布了新的文献求助10
3秒前
4秒前
周小鱼发布了新的文献求助10
4秒前
4秒前
顾矜的应助被陆羽采纳,获得10
5秒前
浅夏给浅夏的求助进行了留言
5秒前
共享精神的应助被h11采纳,获得10
6秒前
orixero的应助被小鱼采纳,获得10
6秒前
SciGPT的应助被samo采纳,获得10
6秒前
7秒前
8秒前
8秒前
9秒前
9秒前
DW的应助被yc采纳,获得10
9秒前
喜悦桥发布了新的文献求助10
9秒前
ZZM发布了新的文献求助10
9秒前
rainbow完成签到,获得积分10
9秒前
NexusExplorer的应助被hushan53采纳,获得10
9秒前
幸运星发布了新的文献求助10
9秒前
10秒前
宋博贤发布了新的文献求助10
11秒前
小鞠佩奇发布了新的文献求助10
12秒前
Ava的应助被阿飞大师采纳,获得10
13秒前
13秒前
初见完成签到,获得积分10
13秒前
hhhh发布了新的文献求助10
13秒前
小星星发布了新的文献求助10
14秒前
14秒前
14秒前
Alinse完成签到,获得积分10
15秒前
kkkkk完成签到 ,获得积分10
15秒前
jx发布了新的文献求助10
15秒前
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8163664
求助须知:如何正确求助?哪些是违规求助? 9557817
关于积分的说明 21741980
捐赠科研通 7754358
什么是DOI,文献DOI怎么找? 3428338
关于科研通互助平台的介绍 2553000
邀请新用户注册赠送积分活动 2472943